# reload+after+2024-01-22 01:45:37.230996
address1§219 Terry Ave. N
address2§Suite 300
city§Seattle
state§WA
zip§98109
country§United States
phone§206 378 0400
website§https://kinetabio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer. It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
fullTimeEmployees§11
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Shawn P.  Iadonato Ph.D.', 'age': 53, 'title': 'Chair of the Board & CEO', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 628659, 'exercisedValue': 0, 'unexercisedValue': 8582}, {'maxAge': 1, 'name': 'Mr. Craig W. Philips', 'age': 62, 'title': 'President', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 485787, 'exercisedValue': 0, 'unexercisedValue': 8582}, {'maxAge': 1, 'name': 'Ms. Pauline  Kenny Esq., J.D.', 'age': 50, 'title': 'General Counsel & Secretary', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 349716, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Keith A. Baker', 'age': 56, 'title': 'Chief Financial Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Thierry  Guillaudeux Ph.D.', 'age': 56, 'title': 'Chief Scientific Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jacques  Bouchy', 'age': 54, 'title': 'Executive Vice President of Investor Relations & Business Development', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kenneth R. North', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
priceToSalesTrailing12Months§5.259032
currency§USD
dateShortInterest§1702598400
forwardEps§-1.15
exchange§NCM
quoteType§EQUITY
shortName§Kineta, Inc.
longName§Kineta, Inc.
firstTradeDateEpochUtc§1455201000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§709960ac-3b08-3407-99b9-a14d0009bc3c
gmtOffSetMilliseconds§-18000000
targetHighPrice§13.5
targetLowPrice§8.0
targetMeanPrice§10.75
targetMedianPrice§10.75
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§2
quickRatio§0.993
grossMargins§1.51358
ebitdaMargins§0.0
trailingPegRatio§None
